|Day Low/High||5.72 / 5.95|
|52 Wk Low/High||0.24 / 1.96|
Phase 2 MDD clinical trial results expected in 3Q17, Extended runway of cash into 3Q18
Investigating New Patient Cohort with Cervical Injury
TheStreet's biotech columnist offers his own report card on biotech stocks.
NSI-189 Shows Reversal of Radiation-induced Cognitive Deficits
NSI-189 Shows Prevention and Reversal of Diabetic Neuropathies in Mice
Dr. Karl Johe Resigns from Board of Directors; Company Announces Creation of Scientific Policy Committee with Dr. Johe as Chairman
Data Contribute to Understanding NSI-189 Mechanism of Action
These under-$10 stocks are ready to move higher from current levels. Here's how to trade them from here.
Trial Efficacy Endpoints Include Reduction in Depression and Cognition Improvement